3.12
+0.97%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Acousort
Its shares trade on Nasdaq Stockholm under the ticker ACOU.ST. It has been listed since 9 January 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 6.9m and a net loss of SEK 12.2m. At that date it held total assets of SEK 17.9m and shareholders' equity of SEK 16.3m.
AcouSort AB engages in the provision of biotechnology. The company is headquartered in Lund, Skane. The company went IPO on 2017-01-09. The firm develops, produces and sells standalone laboratory products and integrated original equipment manufacturer (OEM) solutions where ultrasound is used to separate, wash and enrich cells, exosomes and other biological particles for research and diagnostics. Its product portfolio includes AcouWash and AcouTrap that are targeting separation, washing and enrichment applications within cell, bacteria and extracellular vesicle research. In addition, the Company develops proprietary bioanalytical and clinical applications based on acoustophoresis, and offers custom-developed acoustophoresis applications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Jan 2017
- Website
- acousort.com ↗
Leadership
Pay as last reported
- Torsten Freltoft, PhDChief Executive Officer & Managing Director, since 2014
- Gunnar TelhammarChief Financial Officer, since 2018
- Matts Ole Kristian Enkvist, PhDDirector & Head-Business development
- Martin Olin, EMBAChairman, since 2022
- Martin Linde, EMBADirector, since 2015
- Lars Thomas Laurell, PhDDirector, since 2010
- Stefan Scheding, MDDirector, since 2010
- Matts Ole Kristian Enkvist, PhDDirector & Head-Business development
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Acousort AB's product AcouWash targets cell separation applications in research and diagnostics.
- The company's AcouTrap product is used for washing and enrichment of biological particles in cell research.
- Acousort AB's headquarters in Lund, Skane, provides access to a strong biotechnology sector in Sweden.
Weaknesses
- Acousort AB's IPO occurred in January 2017, which may limit its market presence compared to newer competitors.
- The company's product portfolio is limited to AcouWash and AcouTrap for cell and biological particle applications.
- Acousort AB operates primarily within the biotechnology sector in Sweden, which may restrict its global market reach.
Opportunities
- Acousort AB can expand its product line to include additional applications for acoustophoresis in clinical diagnostics.
- The growing demand for cell separation technologies in research and diagnostics presents a market opportunity for Acousort AB.
- Acousort AB's proprietary bioanalytical applications based on acoustophoresis could be leveraged for new market segments.
Threats
- Acousort AB faces competition from other biotechnology firms in the same sector in Sweden.
- The company's reliance on a single product line (AcouWash and AcouTrap) for revenue may increase vulnerability to market changes.
- Acousort AB's limited global presence compared to international competitors could hinder its ability to capture larger market shares.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.